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TREM-1 Protects HIV-1-Infected Macrophages from Apoptosis
through Maintenance of Mitochondrial Function
Grant R. Campbell,a Rachel K. To,a* Stephen A. Spectora,b
aDivision of Infectious Diseases, Department of Pediatrics, University of California San Diego, La Jolla, California, USA
bRady Children’s Hospital, San Diego, California, USA
ABSTRACT Macrophages are a reservoir for latent human immunodeﬁciency type 1
(HIV) infection and a barrier to HIV eradication. In contrast to CD4 T cells, macro-
phages are resistant to the cytopathic effects of acute HIV infection. Emerging data
suggest a role for TREM1 (triggering receptor expressed on myeloid cells 1) in this
resistance to HIV-mediated cytopathogenesis. Here, we show that upon HIV infec-
tion, macrophages increase the expression of BCL2, BCLXL, TREM1, mitofusin 1
(MFN1), and MFN2 and the translocation of BCL2L11 (BIM) to the mitochondria and
decrease the expression of BCL2-associated agonist of cell death (BAD) and BAX
while maintaining a 95% survival rate over 28 days. The HIV proteins Tat and gp120
and the GU-rich single-stranded RNA (ssRNA) (RNA40) from the HIV long terminal re-
peat region (and a natural Toll-like receptor 8 [TLR8] agonist) induced similar effects.
TREM1 silencing in HIV-infected macrophages led to decreased expression of BCL2,
BCLXL, MFN1, and MFN2 and increased expression of BAD and BAX. This correlated
with a signiﬁcant increase in apoptosis mediated by a disruption of the mitochon-
drial membrane potential (Δm), leading to the release of cytochrome c and caspase
9 cleavage. Exposure of TREM1-silenced macrophages to Tat, gp120, or RNA40 simi-
larly resulted in the disruption of Δm, cytochrome c release, caspase 9 cleavage,
and apoptosis. Thus, our ﬁndings identify a mechanism whereby HIV promotes mac-
rophage survival through TREM1-dependent upregulation of BCL2 family proteins
and mitofusins that inhibits BCL2L11-mediated disruption of Δm and subsequent
apoptosis. These ﬁndings indicate that TREM1 can be a useful target for elimination
of the HIV reservoir in macrophages.
IMPORTANCE The major challenge to human immunodeﬁciency virus (HIV) treat-
ment is the development of strategies that lead to viral eradication. A roadblock to
accomplishing this goal is the lack of an approach that would safely eliminate HIV
from all resting/latent reservoirs, including macrophages. Macrophages are a key
part of the innate immune system and are responsible for recognizing invading mi-
crobes and sending appropriate signals to other immune cells. Here, we found that
HIV induces the upregulation of the protein TREM1 (triggering receptor expressed
on myeloid cells 1), which signals an increase in the expression of antiapoptotic pro-
teins, thus promoting survival of HIV-infected macrophages.
KEYWORDS BCL2 family, TREM-1, apoptosis, human immunodeﬁciency virus,
macrophages, mitochondria, mitofusin
The major obstacle to eradicating human immunodeﬁciency type 1 (HIV-1) is theestablishment of long-lived reservoirs of virus. Although latently infected CD4 T
cells represent the predominant viral reservoir in infected persons on suppressive
antiretroviral therapy (ART), other cell types, including macrophages, serve as important
sites of HIV persistence (1–3). Latently HIV-infected perivascular macrophages contain
replication-competent proviral HIV DNA, support persistent permissive HIV infection in
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the absence of CD4 T cells (4, 5), and contain lower intracellular concentrations of
antiretrovirals than CD4 T cells, resulting in ongoing HIV replication (6). Latently
infected macrophages also harbor and transmit replication-competent virus to nearby
CD4 T cells through virologic synapses that are resistant to antibody-mediated
neutralization (7). Additionally, they survive for months to years and are resistant both
to the cytopathic effects of HIV infection and to CD8 T cell-mediated killing (8–10).
Notwithstanding recent advances deﬁning cell death signaling pathways, much is
unknown about the mechanism(s) by which macrophages escape apoptosis during HIV
infection. Despite this, studies suggest that HIV signals through multiple pathways to
reprogram the transcriptome and proteome of human macrophages to render them
resistant to HIV-mediated apoptosis. HIV Nef induces the phosphorylation and inacti-
vation of proapoptotic BCL2-associated agonist of cell death (BAD) (11), and HIV Tat
and gp120 induce the transcription of apoptosis regulatory proteins, including colony-
stimulating factor 1 (CSF1), caspase 8 (CASP8) and Fas associated via death domain
(FADD)-like apoptosis regulator (CFLAR), BCL2 family members BCL2 and BCLXL, and
inhibitor of apoptosis proteins (IAP) X-linked inhibitor of apoptosis (XIAP), baculoviral
IAP repeat-containing 2 (BIRC2), and BIRC3 (12–14). Additionally, acute exposure to HIV
and to HIV gp41 peptides upregulates triggering receptor expressed on myeloid cells
1 (TREM1) in peripheral blood mononuclear cells (PBMC) and macrophages (15–17).
TREM1 is a 30-kDa glycoprotein expressed on macrophages that belongs to the
immunoglobulin variable (IgV) domain superfamily of proteins and consists of a
positive-charged transmembrane domain and a short cytoplasmic domain that lacks
any signaling motif. Thus, TREM1 requires TYRO protein tyrosine kinase binding protein
(TYROBP) for signaling (18, 19). Although the precise ligands for TREM1 are unknown,
CD177, peptidoglycan recognition protein 1 (PGLYRP1), high-mobility group box 1
protein (HMGB1), and some damage-associated molecular patterns (DAMPs) and
pathogen-associated molecular patterns (PAMPs) activate TREM1 signaling (20–24).
TREM1 ligation leads to an increase in reactive oxygen species and the secretion of
proinﬂammatory cytokines through the activation of NF-B. Additionally, TREM1 liga-
tion synergistically ampliﬁes Toll-like receptor (TLR)-mediated and Nod-like receptor
(NLR)-mediated proinﬂammatory responses (19). TREM1 is also an antiapoptotic mol-
ecule that prolongs macrophage survival. Speciﬁc ligation or overexpression of TREM1
induces BCL2 expression and the subsequent depletion of caspase 3, preventing the
cleavage of PARP1 (25). In addition, both ligation and overexpression of TREM1 lead to
an increase in mitofusin expression levels, suggesting that TREM1 contributes to the
maintenance of mitochondrial integrity, thus favoring cell survival (25). The involve-
ment of and mechanisms by which TREM1 may alter macrophage survival during HIV
infection are unknown. Therefore, we investigated whether TREM1 affects cell survival
during HIV infection of human primary macrophages.
RESULTS
HIV infection of macrophages results in persistent infection and prolongs cell
survival. We designed our initial experiments to determine whether HIV infection
results in increased apoptosis of infected macrophages. We infected macrophages with
HIV for 28 days, during which time we assessed HIV replication kinetics and apoptosis.
HIV p24 antigen levels increased in culture supernatants between day 3 and day
18 followed by a decline after 18 days (Fig. 1A). Uninfected macrophages showed low
levels of apoptosis, with an observed maximum of 13.5% of cells displaying formamide-
sensitive single-stranded DNA (ssDNA; a speciﬁc indicator of apoptosis [26]) by day 28
(Fig. 1B). HIV infection of macrophages was associated with a decrease in cell death,
reaching a high of just 5.5% at day 28 (0.3% standard error of the mean [SEM];
P 0.017) (Fig. 1B). Culture supernatants assessed for lactate dehydrogenase (LDH)
release demonstrated the same proﬁle (Fig. 1C). Collectively, these results suggest that
HIV infection prolongs survival of macrophages.
HIV inﬂuences pro- and antiapoptotic protein expression in macrophages. To
determine why there is an absence of apoptosis in HIV-infected macrophages, we
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analyzed the induction of proapoptotic (BAD and BAX) and antiapoptotic (BCLXL and
BCL2) proteins in HIV-infected macrophages (Fig. 2A). At day 10 postinfection, the
expression levels of two antiapoptotic factors, BCL2 and BCLXL, were increased
(P 0.01) whereas those of the proapoptotic proteins BAX and BAD were decreased
FIG 1 Macrophages were left uninfected (left) or infected with puriﬁed HIV (right) at an MOI of 0.002 to
allow slow progressive infection of cells. (A) ELISA was performed for supernatant HIV p24 antigen over
28 days, n 4. (B) Cells were ﬁxed and permeabilized, and the percentage of cells with apoptotic ssDNA
damage was quantiﬁed by ELISA, n 4. (C) Aliquots of supernatants were spectrophotometrically tested
for LDH using the LDHPLUS assay, n 4.
FIG 2 Macrophages were left uninfected or infected with HIV for 10 days. (A) At day 10 postinfection, cells were harvested, stained
for HIV p17 expression, and analyzed by ﬂow cytometry. Representative histogram plots are shown, n 3. (B) (Left) Representative
Western blots of BCLXL, BCL2, BAD, and BAX with antibodies against BCLXL, BCL2, BAD, BAX, and ACTB. (Right) Densitometric
analysis of blots, n 4. (C) Mitochondria were extracted over time. (Top) Representative Western blots of BCL2L11 with antibodies
against BCL2L11, ACTB, and COX4I1. ACTB was used a control for mitochondrion fraction purity. (Bottom) Densitometric analysis
of blots, n 4.
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(P 0.01; Fig. 2B). Next, we determined if the HIV antigens gp120, Tat, and RNA40 (a
20-mer synthetic single-stranded RNA oligoribonucleotide derived from the HIV long-
terminal repeat and TLR8 ligand) inﬂuenced the expression of these pro- and antiapo-
ptotic proteins in macrophages. Both gp120 and Tat increased the expression levels of
BCL2 and BCLXL in a dose-dependent manner while simultaneously decreasing those
of both BAD and BAX (see Fig. S1 in the supplemental material). In contrast, while
RNA40 also dose dependently increased the expression of both BCL2 and BCLXL, it also
increased the expression of BAD while having no effect on BAX expression levels
(Fig. S1).
A key event in apoptosis is the translocation of BCL2L11 from the cytoskeleton to
the mitochondrial membrane (27). In healthy cells, BCL2L11 is inactivated by its
interaction with dynein light chain LC8-type 1 (DYNLL1), which recruits it to the
microtubule-based dynein motor complex (28). During HIV infection of CD4 T cells,
HIV Tat binds tubulin through a four-amino-acid subdomain of its conserved core
region, altering microtubule dynamics (29, 30) and leading to the mitogen-activated
protein kinase 8 (MAPK8)-mediated phosphorylation of BCL2L11 and dissociation from
DYNLL1 and the dynein motor complex. Phosphorylated BCL2L11 then translocates to
the mitochondrial membrane, where it directly activates the BAX/BAK-dependent
mitochondrial pathway of apoptosis and cell death (27, 31, 32). Therefore, we examined
whether HIV infection also induces the translocation of BCL2L11 to mitochondria in
macrophages despite the absence of HIV-mediated cytopathogenesis. Using cell frac-
tionation, we determined that BCL2L11 translocates to mitochondria, suggesting that
HIV is inhibiting the mitochondrial pathway of apoptosis (Fig. 2C).
HIV infection increases the expression of TREM1 in macrophages. As HIV
infection resulted in increased expression of BCL2 and as overexpression of TREM1
can induce the expression of BCL2 (25), we examined whether macrophages produc-
tively infected with HIV express higher levels of TREM1. At 10 days after infection,
HIV-infected macrophages displayed increased levels of TREM1 (P 0.02; Fig. 3A). We
then investigated the mechanism by which HIV induces TREM1 expression. As NF-B
transcriptionally regulates TREM1 in macrophages in response to LPS (33), we utilized
RNA interference (RNAi) for the NF-B subunit RELA to investigate whether NF-B
regulates TREM1 expression in response to HIV infection. RELA silencing resulted in the
almost complete ablation of TREM1 expression in response to HIV (Fig. 3B), suggesting
that NF-B regulates TREM1 expression in HIV-infected macrophages. To conﬁrm the
sequence-speciﬁc interaction of RELA with the TREM1 promoter, we analyzed the
promoter region of TREM1 using Genomatix (version 3.11; Intrexon) and found con-
sensus binding sites for NF-B. We performed an electrophoretic mobility shift assay
using a biotinylated probe that encompassed the predicted binding site. This probe
showed evidence of strong binding to nuclear proteins and was supershifted by
antibodies against RELA and NFKB1 but not by antibodies against REL, NFKB2, RELB, or
BCL3 (Fig. 3C). To investigate whether HIV triggers the classical NF-B signaling
pathway, we analyzed the ability of RELA to physically interact with NFKB1 p50 and to
translocate to the nucleus using coimmunoprecipitation. NFKB1 p50/RELA complexes
were detected in both the cytoplasm and the nucleus, whereas no NFKB1 p50/RELB
complexes were detected (Fig. 3D). Interestingly, although uninfected cells transfected
with siRELA showed apoptosis levels similar to the levels seen with those transfected
with control RNAi, RELA-silenced HIV-infected macrophages showed an increased
number of apoptotic cells (Fig. 3E; P 0.001).
We next investigated whether HIV gp120, Tat, and RNA40 induce TREM1 expression
in human macrophages. All three antigens induced a dose-dependent increase in
TREM1 expression; HIV Tat and gp120 induced 18-fold (3.9 SEM; P 0.0005) and
7.5-fold (2.9 SEM; P 0.0075) increases, respectively, at 10 ng ml1, and HIV RNA40
induced a 42-fold increase (4.6 SEM; P 0.0001) at 5 g ml1 (Fig. 4A). Similarly to
HIV-infected macrophages, RELA silencing of uninfected macrophages (Fig. 4B and C)
signiﬁcantly increased cell death in response to the presence of HIV Tat, gp120, or
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RNA40 (Fig. 4D), while it also attenuated TREM1 expression (Fig. 4E). Electrophoretic
mobility shift assay (EMSA) demonstrated that HIV Tat, gp120, and RNA40 rapidly
induced NF-B DNA binding, with supershift analysis demonstrating that the NF-B
complex consisted primarily of NFKB1 and RELA subunits (Fig. S2A). We then investi-
gated whether these antigens trigger the classical NF-B signaling pathway. HIV Tat,
gp120, and RNA40 all triggered the rapid processing of NFKB1 p105 to p50, the
dimerization of NFKB1 p50 with RELA, and the subsequent nuclear translocation
(Fig. S2B and C).
TREM1 is required for HIV-infected macrophage survival. To address the role of
TREM1 in macrophage survival during HIV infection, we used TREM1 small interfering
RNA (siRNA). We reasoned that if TREM1 is involved in promoting cell survival, then
silencing TREM1 should increase cell death during HIV infection. Macrophages infected
with HIV for 10 days were transfected with control scrambled siRNA (siNS) or TREM1
siRNA (siTREM1) for 48 h and then either assessed for apoptotic ssDNA damage or
stained with annexin A5 (ANXA5) and propidium iodide (PI) (Fig. 5A). Uninfected cells
transfected with siTREM1 showed apoptosis levels similar to those transfected with
siNS. In contrast, TREM1 siRNA-transfected HIV-infected macrophages showed an in-
creased number of apoptotic cells (83.9% 6%) compared with HIV-infected macro-
phages transfected with siNS (4.2 1.4%; P 0.02). Because TREM1 silencing induced
FIG 3 Macrophages were left uninfected or infected with HIV for 10 days. (A) Cells were harvested and lysed. (Left) Representative
Western blots of TREM1 with antibodies against TREM1 and ACTB. (Right) Densitometric analysis of blots, n 4. (B) Cells were transfected
with RELA siRNA (siRELA) or scrambled siRNA (siNS). (Left) Representative Western blots of RELA, TREM1, and ACTB. (Right) Densitometric
analysis of blots, n 4. (C) Nuclear extracts were prepared and assayed by supershift EMSA using a TREM1 probe and antibodies speciﬁc
for human REL, RELA, NFKB1, NFKB2, RELB, and BCL3. A representative blot is shown, n 4. Ab, antibody. (D) Cytoplasmic and nuclear
fractions were immunoprecipitated (IP) with anti-NFKB1 and were then subjected to Western blotting using anti-RELA or anti-RELB
antibodies. (Right) Representative Western blots. (Left) Densitometric analysis of blots, n 4. (E) Transfected cells from the experiment
whose results are presented in panel B were assessed for apoptotic ssDNA damage by ELISA, n 4.
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apoptosis in productively infected cells, we posited that TREM1 silencing altered the
balance of anti- and proapoptotic proteins. Indeed, TREM1 silencing resulted in a
signiﬁcant reduction in HIV-induced BCLXL and BCL2 expression (P 0.0003) while
having a modest impact on BAD and BAX expression (P 0.06; Fig. 5B).
Next, we analyzed the effect of HIV antigen-induced apoptosis on TREM1-silenced
cells (Fig. 6A) after exposure of the cells to HIV antigens for 24 h. Importantly, exposure
of siNS-transfected cells to HIV Tat, gp120, or RNA40 did not result in increased
FIG 4 (A) Uninfected macrophages were treated with vehicle, Tat, gp120, or RNA40 for 24 h. (Left) Representative Western blots of TREM1
with antibodies against TREM1 and ACTB. (Right) Densitometric analysis of blots, n 4. (B) Uninfected macrophages were transfected with
siRELA or siNS for 48 h. (Left) Representative Western blots of RELA with antibodies against RELA and ACTB. (Right) Densitometric analysis
of blots, n 4. (C) The transfection efﬁciency of Lipofectamine RNAiMAX in macrophages was assessed using BLOCK-iT Alexa Fluor red
ﬂuorescent control. Cells were harvested 24 h posttransfection and analyzed by ﬂow cytometry. (Left) A representative histogram is
shown. (Right) Percentages of cells positive for BLOCK-iT Alexa Fluor red, n 8. (D) Uninfected macrophages were transfected with siRELA
or siNS for 48 h and then treated with vehicle, Tat, gp120, RNA40, RNA41 (R41), or staurosporine (STS) for 24 h. Apoptotic ssDNA damage
was quantiﬁed by ELISA, n 4. (E) Uninfected macrophages were transfected with siRELA or siNS for 48 h and then treated with vehicle,
Tat, gp120, RNA40, or RNA41 (R41) for 24 h. (Left) Representative Western blots of TREM1 with antibodies against TREM1 and ACTB. (Right)
Densitometric analysis of blots, n 4.
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apoptosis (P 0.4; Fig. 6B). In contrast, and similarly to HIV infection, TREM1-silenced
macrophages treated with HIV antigens displayed an enhanced number of apoptotic
cells compared with vehicle-treated cells (Fig. 6B). TREM1-silenced cells exposed to Tat
exhibited the highest proportion of apoptotic cells (mean, 92.4 0.4%; P 0.0001)
closely followed by RNA40 (mean, 84.7% 1.3%; P 0.0001) and gp120 (mean,
73.5% 2.2%; P 0.0001). Importantly, staurosporine exposure similarly induced ap-
optosis in both siNS-transfected and siTREM1-transfected cells (mean, 94.5% 1.4%
versus 94.0% 0.4%; P 0.4) (Fig. 6B). We then evaluated the effect of TREM1 silencing
on HIV antigen-induced expression of antiapoptotic and proapoptotic proteins. TREM1
silencing decreased BCLXL and BCL2 expression in uninfected macrophages by more
than 86% (P 0.001) while having no noticeable effect on the expression of either BAX
or BAD (Fig. 6C). Of note, neither HIV Tat nor gp120 nor RNA40 had a signiﬁcant effect
on the expression of BCLXL, BCL2, BAX, or BAD compared to the vehicle in these
TREM1-silenced cells. Collectively, these data suggest that induction of TREM1 by HIV
inhibits apoptosis and prolongs survival of HIV-infected macrophages.
FIG 5 Uninfected macrophages and macrophages infected with HIV for 10 days were transfected with
siTREM1 or siNS for 48 h. (A) Cells were assessed for cell death. (Top left) Cells were harvested and stained
with annexin V (ANXA5) and PI. The frequency of ANXA5-positive or ANXA5/PI-positive labeling is
illustrated as a plot. (Right) Representative dot plots representing cells from a single donor are shown.
(Bottom left) Quantiﬁcation of the number of cells with apoptotic ssDNA damage by the use of ssDNA
ELISA, n 4. (B) Cells were lysed and subjected to Western blotting. (Left) Representative Western blots
of BCLXL, BCL2, BAD, BAX, and TREM1 with antibodies against BCLXL, BCL2, BAD, BAX, TREM1, and ACTB.
(Right) Densitometric analysis of blots, n 4.
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Next, we sought to deﬁne the expression of BCL2 in relation to speciﬁc ligation of
TREM1 by the use of monoclonal antibodies (mTREM1). BCL2 expression was signiﬁ-
cantly increased in macrophages in response to mTREM1 compared with the isotype
control antibody (P 0.0006; Fig. 7A). We then sought to deﬁne the relationship
between BCL2 expression and cell survival during HIV infection of macrophages using
RNAi for BCL2. BCL2 silencing of HIV-infected macrophages led to an increased number
of apoptotic cells (86.3% 5.4%; P 0.0001) (Fig. 7B). Similarly, BCL2 silencing also
signiﬁcantly increased uninfected macrophage cell death in response to exposure to
HIV Tat, gp120, or RNA40 (P 0.001; Fig. 7C).
TREM1 silencing leads to the induction of apoptosis through the intrinsic
pathway. The interactions between anti- and proapoptotic proteins exist in a delicate
balance at the mitochondrial membrane that determines cell fate, with mitochondrial
fragmentation a central mechanism of apoptosis. Loss of balance between pro- and
antiapoptotic BCL2 proteins leads to outer membrane permeabilization of mitochon-
dria, calcium inﬂux, and mitochondrial fragmentation, leading to the subsequent
activation of effector caspases. In contrast, a fused mitochondrial phenotype protects
cells from programmed cell death. Therefore, we examined the effect of TREM1
silencing on the mitochondrial membrane potential (Δm) using DiIC1(5) (1,1=,3,3,3=,3=-
hexamethylindodicarbo-cyanine iodide). Following TREM1 silencing, there was no dif-
ference in Δm levels between siNS-transfected HIV-infected and uninfected macro-
FIG 6 Uninfected macrophages were transfected with siTREM1 or siNS for 48 h and then treated with vehicle, 10 ng ml1 Tat, 10 ng ml1 gp120, 5 g ml1
RNA40, or 5 g ml1 RNA41 for 24 h. (A) Cells were assessed for TREM1 expression. (Left) Representative Western blots of TREM1 with antibodies against TREM1
and ACTB. (Right) Densitometric analysis of blots, n 4. (B) Cells were assessed for cell death. (Left) Cells were harvested and stained with annexin V (ANXA5)
and PI. The frequency of ANXA5-positive or ANXA5/PI-positive labeling is illustrated as a plot. (Right) Quantiﬁcation of the number of cells with apoptotic ssDNA
using an ssDNA ELISA, n 4. (C) Cells were lysed and subjected to Western blotting. (Left) Representative Western blots of BCLXL, BCL2, BAD, and BAX with
antibodies against BCLXL, BCL2, BAD, BAX, and ACTB. (Right) Densitometric analysis of blots, n 4.
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phages, indicating that mitochondria are still functional during infection. Similarly, we
observed no difference in Δm levels between uninfected cells transfected with
siTREM1 and those transfected with siNS. In contrast, we observed a marked decrease
in DiIC1(5) staining intensity in TREM1-silenced HIV-infected macrophages (Fig. 8A).
These data suggest that TREM1 silencing results in the depolarization of the Δm in
HIV-infected macrophages but not in uninfected macrophages.
A key event in apoptosis is the formation of the transition pore in the mitochondrial
membrane and the release of mitochondrial factors such as cytochrome c (CYCS) into
FIG 7 (A) Uninfected macrophages were exposed to 10 g ml1 TREM1 monoclonal antibody (mAb) for
16 h. Cells were then lysed and assessed by Western blotting. (Left) Representative Western blots of BCL2
with antibodies against BCL2 and ACTB. (Right) Densitometric analysis of blots, n 4. (B) Uninfected
macrophages and macrophages infected for 10 days with HIV were transfected with siBCL2 or siNS for
48 h. (Left top) Cells were lysed and subjected to Western blotting with antibodies against BCL2 and
ACTB. (Left bottom) Densitometric analysis of blots. (Right) quantiﬁcation of the number of cells with
apoptotic ssDNA by the use of ssDNA ELISA, n 4. (C) Uninfected macrophages were transfected with
siBCL2 or siNS for 48 h. (Left top) Cells were lysed and subjected to Western blotting with antibodies
against BCL2 and ACTB. (Left bottom) Densitometric analysis of blots. (Right) quantiﬁcation of the
number of cells with apoptotic ssDNA by the use of ssDNA ELISA, n 4.
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the cytoplasm. To determine whether TREM1 silencing in HIV-infected macrophages
leads to the mitochondrial release of CYCS into the cytoplasm, we performed cell
fractionation. Our data indicate that mitochondria retain CYCS in siNS-transfected
HIV-infected and uninfected cells (Fig. 8B). In contrast, TREM1 silencing induces the
release of CYCS into the cytoplasm in HIV-infected macrophages but not in uninfected
macrophages (P 0.018; Fig. 8B). In the presence of ATP/dATP, CYCS released into the
cytosol binds to and triggers the oligomerization of cytosolic apoptotic protease
activating factor 1 (APAF1). The resultant complex recruits and activates multiple copies
of the apical caspase in the mitochondrial pathway of apoptosis, caspase 9 (CASP9).
TREM1 silencing resulted in the cleavage and activation of CASP9 in HIV-infected
macrophages but had no effect on CASP9 activation in uninfected macrophages
(Fig. 8C).
We next assessed the effect of HIV Tat, gp120, and RNA40 on Δm, CYCS release,
and subsequent CASP9 activation in uninfected macrophages. There was no signiﬁcant
difference in Δm after Tat, gp120, and RNA40 exposure in siNS-transfected macro-
phages, indicating that Tat, gp120, and RNA40 have little effect on Δm in the presence
of TREM1 (Fig. S3A). In contrast, we observed a marked decrease in DiIC1(5) staining
intensity in TREM1-silenced macrophages after Tat, gp120, and RNA40 treatment,
suggesting that TREM1 is essential for maintaining Δm after exposure to HIV antigens.
Similarly, treatment of siNS-transfected macrophages with HIV Tat, gp120, or RNA40 did
not induce the release of CYCS into the cytosol or induce CASP9 cleavage (Fig. S3B). In
contrast, HIV Tat, gp120, and RNA40 exposure of TREM1-silenced cells resulted in CYCS
release from the mitochondria and subsequent CASP9 cleavage. Together, these results
indicate that TREM1 is essential for macrophage survival of acute HIV infection.
TREM1 enhances mitochondrial integrity by inducing mitofusin expression. At
the molecular level, mitochondrial fusion is a two-step process requiring the coordi-
nated fusion of outer and inner mitochondrial membranes by separable sequential
events. In humans, this process depends on distinct mitochondrial sublocalization of
three fusogenic proteins: mitofusins 1 and 2 (MFN1 and MFN2) (embedded within the
outer mitochondrial membrane) and optic atrophy 1 (located at the inner mitochon-
drial membrane). In addition to the well-characterized role of the proﬁssion dynamin-
FIG 8 Uninfected macrophages and macrophages infected for 10 days with HIV were transfected with siTREM1 or siNS for 48 h.
Silencing was performed as described for the experiment whose results are shown in Fig. 5B. (A) Cells were stained with DiIC1(5)
and then harvested and analyzed by ﬂow cytometry. (Left) Representative histograms of DiIC1(5). (Right) Geometric mean
ﬂuorescence intensity illustrated as a plot, n 4. (B) Cells were harvested, fractionated for cytoplasmic content, and assessed by
Western blotting. (Left) Representative Western blots of CYCS and COX4I1 with antibodies against CYCS, COX4I1, and ACTB. (Right)
Densitometric analysis of blots, n 4. (C) Cells were harvested and assessed by Western blotting. (Left) Representative Western
blots of CASP9 and cleaved CASP9 [cCASP9(37) and cCASP9(35)] with antibodies against CASP9 and ACTB. (Right) Densitometric
analysis of blots, n 4.
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1-like protein in mediating mitochondrial ﬁssion in cells undergoing cell death, inhibi-
tion of mitochondrial fusion is also an established consequence of apoptosis induction
and occurs around the time of BAX activation. During oxygen glucose deprivation,
MAPK1/2 phosphorylates MFN1, inhibiting its profusion function, and triggers its
association with and oligomerization of BAK, facilitating the subsequent release of
CYCS from mitochondria through BCL2L11 (34). Similarly, in response to cellular
stresses, MAPK8 phosphorylates MFN2, leading to its ubiquitin-dependent proteasomal
degradation and subsequently to mitochondrial fragmentation and enhanced apopto-
tic cell death (35). Therefore, we assessed mitofusin expression in HIV-infected macro-
phages. We found that at day 10 postinfection, the expression levels of both MFN1 and
MFN2 were increased (P 0.007; Fig. 9A). We next assessed the effect of HIV Tat, gp120,
and RNA40 on mitofusin expression. All three antigens induced dose-dependent
increases in both MFN1 and MFN2 (Fig. S4A).
We next assessed the effect of TREM1 silencing on mitochondrial integrity in
HIV-infected cells by determining mitofusin expression post-TREM1 RNAi treatment.
TREM1 silencing resulted in a signiﬁcant reduction in HIV-induced MFN1 and MFN2 to
levels similar to those seen with uninfected cells (P 0.3; Fig. 9B). When we exposed
TREM1-silenced uninfected macrophages to HIV Tat, gp120, or RNA40, each still in-
creased MFN1 expression, although the increase was appreciably less than in the siNS
cells (Fig. S4B). In contrast, TREM1 silencing reduced MFN2 expression in all treatments,
including the vehicle treatment. Notably, this decrease was signiﬁcantly enhanced
post-HIV Tat treatment (mean, 87% 1.5% reduction; P 0.0001), gp120 treatment
(mean, 89% 0.5% reduction; P 0.0001), and RNA40 treatment (mean, 85% 1.5%
reduction; P 0.0007) compared with the vehicle. These data suggest that TREM1
expression is required for the HIV-mediated upregulation of mitofusins.
DISCUSSION
Efforts to purge the latent HIV reservoir predominantly involve reactivation of viral
production from latently infected CD4 T cells followed by clearance of these cells
through a combination of viral and cell-mediated cytotoxicity while ART prevents
subsequent rounds of infection. Although this strategy has shown promise in cell lines,
it has been ineffective on primary resting CD4 T cells from patients on suppressive
ART and in in vivo studies (36–40). This approach is even less effective in macrophages,
as HIV-infected macrophages are particularly resistant to HIV-mediated apoptosis and
CD8 T cell-mediated killing (8–10). Thus, we require an improved understanding of the
precise mechanisms underlying resistance of macrophage and microglia to cytopathic
effects of HIV in order to develop approaches capable of efﬁciently and effectively
eliminating infected cells. Depleting HIV-infected macrophages may result in the
decline of cytokine and chemokine production and hence suppress the excessive
inﬂammation and aberrant immune cell recruitment that persists despite suppressive
ART and which has been associated with poor prognosis and ongoing viral replication.
The present study demonstrated that HIV upregulates the expression of TREM1 in
FIG 9 (A) Macrophages were left uninfected or infected with HIV for 10 days. (Left) Representative Western blots of MFN1 and
MFN2 with antibodies against MFN1, MFN2, and ACTB. (Right) Densitometric analysis of blots, n 4. (B) Uninfected macrophages
and macrophages infected for 10 days with HIV were transfected with siTREM1 or siNS for 48 h. (Left) Representative Western blots
of MFN1 and MFN2 with antibodies against MFN1, MFN2, and ACTB. (Right) Densitometric analysis of blots. Silencing was
performed as described for the experiment whose results are shown in Fig. 5B, n 4.
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macrophages and that expression of TREM1 is essential in protecting HIV-infected
macrophages from HIV-induced apoptosis.
Infected macrophages display an increase in the levels of expression and recruit-
ment of the proapoptotic protein BCL2L11 into mitochondria. Proapoptotic BH3-only
proteins such as BCL2L11 bind to antiapoptotic proteins, allowing the proapoptotic
multidomain proteins BAX and BAK1 to oligomerize and form channels on the mito-
chondrial membrane and leading to CYCS release and apoptosis. It is possible that the
observed upregulation and sequestration of BCL2L11 into the mitochondria of HIV-
infected macrophages are early steps in the apoptotic response to a viral infection, a
response that HIV subsequently blocks downstream as we do not observe the release
of CYCS from mitochondria nor an increase in apoptosis once infection is estab-
lished. However, when we silenced TREM1, the expression levels of BCL2, BCLXL,
and mitofusins all decreased, while the expression levels of BAX and BAD remained
unchanged. This coincided with the release of CYCS from mitochondria and an
increase in apoptosis.
Although TREM1 activity was initially described only in the context of bacterial or
fungal infections, a role for TREM1 during viral infections is emerging. Early studies
focused on and demonstrated that TREM1 signaling modulates pattern recognition
receptor virus-associated inﬂammation and that TLR signaling upregulates TREM1
expression. TLR3, TLR7, TLR8, and TLR9 are all common TLRs that respond to viral
PAMPs. For example, TREM1-activated murine bone marrow-derived dendritic cells
display increased tumor necrosis factor (TNF) expression after treatment using CpG
DNA (a TLR9 ligand) (41). Similarly, TREM1-activated PBMC display enhanced produc-
tion of TNF following stimulation with either CpG DNA or the TLR3 ligand poly(I●C) (42);
poly(I●C) induces transcription of TREM1 in human primary monocytes (43). In neutro-
phils, TREM1 activation acts synergistically with TLR7 and TLR8 ligand-mediated acti-
vation with regard to effector mechanisms but does so antagonistically for survival (44).
In the present study, we demonstrated that RNA40, a TLR8 ligand, upregulates TREM1
expression and that TREM1 is required for macrophage survival. With regard to viral
infections, West Nile virus (WNV) increases TREM1 expression in murine macrophages
and dendritic cells (45) and enhances TREM1 signaling in murine livers (46). Consistent
with this, exogenous activation of TREM1 increases expression levels of the interferon
alpha 2 gene (IFNA2), TNF, and the interleukin-6 gene (IL-6) in WNV-infected murine
embryonic ﬁbroblasts, while antagonizing TREM1 leads to a reduction in their expres-
sion, suggesting that TREM1 plays a role in modulating the inﬂammatory response to
WNV (45). Similarly, Zika virus also upregulates TREM1 signaling (47). Furthermore, the
Filoviridae Marburg virus and Ebola virus both upregulate the expression and activation
of TREM1 on neutrophils following internalization (20). Although Ebola virus does not
replicate in these cells, it is possible that Ebola virus glycoprotein, which interacts with
neutrophils, acts as a ligand for TREM1 and contributes to the cytokine storm associated
with the terminal stage of Ebola virus infection (20, 48, 49). While we showed that HIV
infection of macrophages increases TREM1 expression and is essential for cell survival,
the role of TREM1 in the inﬂammatory response to HIV infection remains to be
elucidated.
Cells also shed soluble TREM1 (sTREM1) from cell membranes. Although the role of
sTREM1 in the context of viral pathogenesis is unknown, sTREM1 levels are increased
during infection with a number of viruses, including Crimean-Congo hemorrhagic fever
orthonairovirus (50), hepatitis B virus (51), WNV (45), dengue virus (52), and hepatitis C
virus (51). It is possible that such increases in the levels of sTREM1 could represent a
virally induced compensatory mechanism to counteract inﬂammatory processes. Alter-
natively, such increases could represent a host-induced mechanism to control tissue
damage by attenuating downstream inﬂammatory signals. Studies are required to
elucidate this function and to identify the potential of sTREM1 as a marker of disease
severity in acute infections by such viruses as inﬂuenza virus and dengue virus or in
chronic infections such as HIV.
Evading apoptosis by upregulation of antiapoptotic or downregulation of proapo-
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ptotic proteins is an important step in altering cell survival. Importantly, the inhibition
of macrophage apoptosis may contribute to viral latency and persistence during HIV
infection (10, 53). In summary, this study demonstrated an important role and a
mechanism for TREM1 in prolonging survival of HIV-infected macrophages. Our report
also highlights TREM1 as a therapeutic target to clear the macrophage HIV reservoir and
suggests that current HIV reservoir paradigms include the targeting of TREM1 in any
effort to achieve HIV eradication.
MATERIALS AND METHODS
Macrophages. Venous blood was drawn from human subjects using protocols approved by the
Human Research Protections Program of the University of California, San Diego, in accordance with the
requirements of the Code of Federal Regulations (CFR) on the Protection of Human Subjects (45 CFR 46
and 21 CFR 50 and 56). All volunteers gave written informed consent prior to their participation. PBMC
were isolated from whole blood by density gradient centrifugation over Ficoll-Paque Plus (GE Health-
care). Macrophages were prepared by incubating 6 106 PBMC ml1 in macrophage media (RPMI 1640
[Gibco] supplemented with 10% [vol/vol] heat-inactivated fetal bovine serum [FBS; Sigma]; 2 mM
L-glutamine, 0.1 mg ml1 streptomycin, and 100 U ml1 penicillin [all Gibco]; and 10 ng ml1 CSF1
(Peprotech]), after which nonadherent cells were removed by aspiration and washed with Dulbecco’s
phosphate-buffered saline (Gibco). Adherent cells were further incubated in macrophage media for 10
days at 37°C and 5% CO2, with medium changes performed every 2 days, before use. This protocol results
in a high proportion of CD14 sialic acid binding Ig-like lectin 1 (SIGLEC1)Lo macrophages that are
permissive to HIV infection (54, 55).
HIV. HIV Ba-L was obtained through the NIH AIDS Reagent Program from Suzanne Gartner, Mikulas
Popovic, and Robert Gallo (56, 57). Virus stocks were prepared as previously described (58). HIV infectivity
levels were calculated as the 50% tissue culture infectious doses (TCID50) as described previously (59) and
multiplicity of infection (MOI) levels conﬁrmed using TZM-bl cells (from John C. Kappes, Xiaoyun Wu, and
Tranzyme Inc.) (60). Macrophages were infected with HIV at an MOI of 0.04 unless otherwise stated.
Chemicals. HIVBa-L gp120 (AAA44191.1) was obtained through the NIH AIDS Reagent Program.
LyoVec precomplexed RNA40 (catalog no. tlrl-lrna40) and LyoVec precomplexed RNA41 (a derivative of
RNA40 in which adenosine replaced all uracil nucleotides; catalog no. tlrl-lrna41) were purchased from
InvivoGen. Full-length HIV Tat (B.FR.83.HXB2; K03455 [61]) was prepared on 0.5 mmol 4(hydroxy-
methyl)phenoxymethyl-copolystyrene-1% divinylbenzene-resin (Applied Biosystems) using an Applied
Biosystems 433A peptide synthesizer with FastMoc Chemistry as previously described (62). Peptides were
deprotected and cleaved from the support using triﬂuoroacetic acid supplemented with 5% (vol/vol)
H2O, 10% (vol/vol) (methylsulfanyl)benzene, and 5% (vol/vol) ethane-1,2-dithiol. Crude product was
precipitated in 2-methoxy-2-methylpropane at –20°C, washed several times, ﬁltered, and dried under
vacuum. Tat was puriﬁed by reverse-phase high-performance liquid chromatography (HPLC) as previ-
ously described (29). HPLC analysis was performed as previously described (62), amino acid analysis was
performed on a Beckman model 6300 amino acid analyzer, mass spectrometry was carried out using an
Ettan matrix-assisted laser desorption ionization–time of ﬂight apparatus (Amersham Biosciences), and
concentrations were determined using a Beckman DU640 UV light-visible light spectrometer and an
extinction coefﬁcient of 8,480 M1 cm1 (63). Staurosporine (Sigma) was used at 1 M. Monoclonal
TREM1 antibody was purchased from R&D Systems (catalog no. MAB1278; RRID:AB_2208452).
Apoptosis assays. Cell death was estimated using Alexa Fluor 488-tagged ANXA5 and PI staining on
a FACSCalibur ﬂow cytometer and analyzed using CellQuest Pro (both BD Biosciences). Apoptotic ssDNA
damage measurements were made using an ssDNA apoptosis enzyme-linked immunosorbent assay
(ELISA) kit (Millipore) as described previously (64). To assess the extent of necrotic cell death, the lactate
dehydrogenase (LDH) activity of supernatants was measured using a mixture of diaphorase/NAD and
3-(4-iodophenyl)-2-(4-nitrophenyl)-5-phenyl-2H-tetrazol-3-ium chloride/sodium 2-hydroxypropanoate
and percent cytotoxicity calculated according to the protocol of the manufacturer (Roche). The mito-
chondrial membrane potential (Δm) gradient was measured by ﬂow cytometry using 50 nM
1,1=,3,3,3=,3=-hexamethylindodicarbo-cyanine iodide [DiIC1(5); Molecular Probes].
Flow cytometry. Intracellular staining of HIV p17 was performed as previously described (65) using
rabbit anti- mouse anti-gag-p17 (Abcam catalog no. ab9067; RRID:AB_306976) followed by ﬂuorescein
isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology catalog no. sc-2010;
RRID:AB_631735).
siRNA transfection. Macrophages were transfected with Thermo Fisher Silencer Select BCL2 (iden-
tiﬁer [ID] s1916), RELA (ID s11915), TREM1 (ID s28910), or control (catalog no. 4390846) siRNA (siNS) using
Lipofectamine RNAiMAX transfection reagent (Thermo Fisher) in Opti-MEM (Gibco) according to the
manufacturer’s instructions. At 48 h, cells were analyzed for target gene silencing and used in experi-
ments. Transfection efﬁciency was assessed with BLOCK-iT Alexa Fluor red ﬂuorescent control (Thermo
Fisher) using ﬂow cytometry.
Western blotting. The following antibodies were used: anti-ACTB from Sigma (catalog no. A2228;
RRID:AB_476697); anti-TREM1 from Abcam (catalog no. ab90808; RRID:AB_2050414); and anti-BAD
(catalog no. 9268S; RRID:AB_823433), anti-BAX (catalog no. 5023; RRID:AB_2744530), anti-BCL2 (catalog
no. 15071; RRID:AB_2744528), anti-BCL2L11 (catalog no. 2933; RRID:AB_1030947), anti-BCLXL (catalog no.
2764; RRID:AB_2228008), anti-CASP3 (catalog no. 9662; RRID:AB_331439), anti-CASP9 (catalog no. 9502;
RRID:AB_2068621), anti-CYCS (catalog no. 9502; RRID:AB_2637071), anti-H3C1 (catalog no. 4499; RRID:
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AB_10544537), anti-MFN1 (catalog no. 14739; RRID: AB_2744531), anti-MFN2 (catalog no. 9482; RRID:
AB_2716838), anti-NFKB1 (catalog no. 13586; RRID:AB_2665516), and anti-RELA (catalog no. 8242;
RRID:AB_10859369) from Cell Signaling Technology.
Whole-cell lysates were prepared using 20 mM HEPES (Gibco), 150 mM NaCl (Fisher), and 1 mM EDTA
(Sigma) supplemented with 1% (vol/vol) Triton X-100 (Sigma) and 1% (vol/vol) Halt protease and
phosphatase inhibitor cocktail (Thermo Scientiﬁc). Cytoplasmic fractions for parallel mitochondrion
analysis were prepared using a mixture containing 220 mM D-mannitol, 68 mM sucrose, 50 mM
piperazine–N,N=-bis(2-ethanesulfonic acid)–KOH (pH 7.4), 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM
dithiothreitol (all Sigma), and 1% (vol/vol) Halt protease and phosphatase inhibitor cocktail. After 30 min
on ice, cell homogenates were spun at 14,000 g for 15 min and supernatants harvested. For mito-
chondrion preparations, 1 107 macrophages were scraped and pelleted by centrifugation at 800 g
for 10 min. Cells were resuspended in 1.2 ml cold mitolysis buffer (20 mM HEPES [pH 7.5], 10 mM KCl,
1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethanesulfonyl ﬂuoride [all
Sigma]) and incubated for 3 min on ice. Cells were homogenized with 10 strokes of a 27-gauge needle
and centrifuged at 750 g for 15 min at 4°C. The supernatant (cytosolic fraction) was removed, and the
pellet containing mitochondria was resolved in 50 l mitolysis buffer. Cytoplasmic and nuclear fractions
were prepared for coimmunoprecipitation and EMSA using NE-PER nuclear and cytoplasmic extraction
reagent according to the protocol of the manufacturer (Thermo Fisher). For coimmunoprecipitation,
50 g anti-NFKB1 (Cell Signaling Technology catalog no. 12540; RRID:AB_2687614) was immobilized
using a coupling gel and then 50-g amounts of cell lysates were incubated with the antibody-
immobilized coupling gel using a Thermo Scientiﬁc-Pierce coimmunoprecipitation kit. Lysates were
resolved using a 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol-buffered 12% poly-
acrylamide gel and transferred to 0.2-m-pore-size nitrocellulose membranes (Thermo Scientiﬁc), fol-
lowed by detection with primary antibodies, alkaline phosphatase-tagged secondary antibodies
(Invitrogen), and 0.25 mM disodium 2-chloro-5-(4-methoxyspiro {1,2-dioxetane-3,2=-(5=-chloro)tricyclo-
[3.3.1.13,7]decan}-4-yl)-1-phenyl phosphate supplemented with 5% (vol/vol) Nitro-Block II (both Applied
Biosystems). The densities of the target bands were compared to that of the applicable reference, i.e.,
ACTB (for whole-cell lysates and cytoplasm fractions), COX4I1 (for mitochondrion fractions), or H3C1 (for
nuclear fractions), and the data were calculated using ImageJ (NIH).
Electrophoretic mobility shift assay. EMSA was conducted using a LightShift chemiluminescent
EMSA kit (Thermo Fisher) according to the manufacturer’s instructions using the following biotin
end-labeled duplex DNA oligonucleotide: 5=-AAGTGTTTCACTCTGGATCTTATCCTTCAAAGGTCCACTTTTAA
AAATTT-3=. For supershift experiments, nuclear extracts were preincubated with one of the following
antibodies: anti-NFKB1 (catalog no. 13586; RRID:AB_2665516), anti-NFKB2 (catalog no. 3017; RRID:
AB_10697356), anti-REL (catalog no. 67489; RRID:AB_2799726), or anti-RELA (catalog no. 8242; RRID:
AB_10859369) from Cell Signaling or anti-BCL3 (catalog no. PA5-28783; RRID:AB_2546259) from Thermo
Fisher. Binding reactions were resolved on a 3% to 12% NativePAGE Bis-Tris gel (Thermo Fisher) and
transferred to nylon membranes (Thermo Fisher).
Statistics. Sample sizes are stated in the ﬁgure legends and refer to the number of independent
replicates (n). Data are represented as dot blots with means  95% conﬁdence intervals. Data were
assessed for symmetry, or skewness, using Pearson’s skewness coefﬁcient. Normalized ratiometric data
were log2 transformed. When the level of protein expression in the reference sample was zero, we used
proportion statistics to detect differences (58, 66). Comparisons between groups were performed using
the paired, two-tailed Student’s t test. In all experiments, differences were considered signiﬁcant when
the P value was less than 0.05 (*, P 0.05).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
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FIG S1, TIF ﬁle, 2.9 MB.
FIG S2, TIF ﬁle, 2.5 MB.
FIG S3, TIF ﬁle, 2.9 MB.
FIG S4, TIF ﬁle, 2.9 MB.
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